Hyaline Membrane Disease

A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS).

Also Known As:

Networked: 498 relevant articles (17 outcomes, 34 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Patent Ductus Arteriosus
2.	Birth Weight (Birth Weights)
3.	Lung Injury
4.	Hemorrhage
5.	Pneumothorax

Experts

1.	Capoluongo, Ettore: 2 articles (05/2012 - 10/2008)
2.	De Luca, Daniele: 2 articles (05/2012 - 10/2008)
3.	Conti, Giorgio: 2 articles (05/2012 - 10/2008)
4.	Romagnoli, Costantino: 2 articles (01/2010 - 10/2008)
5.	Roth-Kleiner, Matthias: 2 articles (11/2007 - 05/2003)
6.	Franco, Marie-Laure: 2 articles (11/2002 - 05/2002)
7.	Jarreau, Pierre-Henri: 2 articles (11/2002 - 05/2002)
8.	Dassieu, Gilles: 2 articles (11/2002 - 05/2002)
9.	Delacourt, Christophe: 2 articles (11/2002 - 05/2002)
10.	Danan, Claude: 2 articles (11/2002 - 05/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hyaline Membrane Disease:

1.	OxygenIBA 07/01/1991 - "Among the subgroup of 237 infants with hyaline membrane disease, median fractional inspired oxygen at the time of entry to the trial was 0.6 in the HFPPV group and 0.7 in the LFPPV group, indicating that many had moderately severe disease. " 07/01/1986 - "Significant antecedents of haemorrhage similar to those found in the previous study included severe bruising, low arterial:fractional inspiratory oxygen ratio and low packed cell volume on admission, hyaline membrane disease, hypercarbia, and hypoxaemia. " 11/01/1961 - "Maternal-fetal oxygen and acid-base studies and their relationships to hyaline membrane disease in the newborn infant." 09/01/1958 - "Hyaline membrane disease: the influence of high oxygen concentration on ciliary activity in the respiratory tract: an experimental study on rabbits." 10/01/2011 - "In general, if a premature infant with hyaline membrane disease, as it was called respiratory distress syndrome (RDS), could not maintain a pO(2) above 60 mmHg in 100% oxygen, it was not expected to survive. "
2.	Tolazoline (Priscoline)FDA Link 02/01/1979 - "Effect of tolazoline in severe hyaline membrane disease." 01/01/1978 - "An immediate response to tolazoline, a rise in PaO2 of 15 torr or more within 15 min, was seen in 11 infants in the hyaline membrane disease group and in eight infants of the other group. " 02/01/1979 - "Tolazoline hydrochloride was given as a pulmonary vasodilator to 20 preterm infants with severe hyaline membrane disease requiring mechanical ventilation who developed persistent severe hypoxaemia. " 06/01/1990 - "Effect of tolazoline on persistent hypoxemia in severe hyaline membrane disease." 09/01/1979 - "Usefulness of tolazoline in severe hypoxemia and acidosis complicating hyaline membrane disease: report of case."
3.	beractant (Survanta)FDA Link 04/01/2002 - "We tested the hypothesis that the initial functional residual capacity (FRC) of preterm infants with hyaline membrane disease (HMD) could predict the response to surfactant replacement (Survanta, 4 mL/kg/dose), with a better initial FRC being correlated with a greater improvement in PaO2, a/A PO2 ratio, and FRC. " 06/01/1985 - "As a prelude to clinical trials with a bovine surfactant (surfactant TA), in human infants with hyaline membrane disease, pulmonary and hemodynamic changes following its instillation in premature baboons were investigated. " 03/01/2001 - "Early administration of the second dose of surfactant (beractant) in the treatment of severe hyaline membrane disease." 12/01/1989 - "We conducted a clinical trial to assess whether surfactant-TA given within the first six hours of life could improve oxygenation and reduce the ventilatory support in premature infants with hyaline membrane disease (HMD) during the first 24 hours of life. " 02/01/1988 - "Because the issue of optimal time for artificial surfactant therapy for hyaline membrane disease has not been established, the effects of treatment with a reconstituted bovine surfactant (surfactant TA) were compared at two time periods in a hyaline membrane disease model in a premature baboon. "
4.	Pulmonary Surfactants (Pulmonary Surfactant)IBA 12/01/1989 - "A case of hyaline membrane disease was treated successfully with pulmonary surfactant (PS) isolated from human amniotic fluid. " 04/01/2007 - "[Study of treatment of hyaline membrane disease with pulmonary surfactant replacement in premature infant]." 05/01/2008 - "About 5 years later Mary Ellen Avery and Jere Mead published convincing evidence that preterm neonates dying of hyaline membrane disease (respiratory distress syndrome, RDS) had a deficiency of pulmonary surfactant. " 07/01/1993 - "It is concluded that meeting the recommended requirements for its use, the pulmonary surfactant is a therapeutic alternative in the treatment of hyaline membrane disease in newborn infants of less than 33 weeks gestation, being different the immediate ventilatory response in terms of therapeutic control, with one or other forms of pulmonary exogenous surfactant, without differences in the final result." 07/01/1993 - "Preliminary report of our experience with the therapeutic use of pulmonary surfactant in newborn infants of less than 30 weeks gestation with hyaline membrane disease. "
5.	Indomethacin (Indometacin)FDA LinkGeneric 10/01/2001 - "Independent variables found to increase the risk of unsuccessful closure with indomethacin significantly were caesarean section, lower haematocrit at delivery and severity of hyaline membrane disease. " 11/01/1987 - "To determine the efficacy of indomethacin to prevent the occurrence of symptomatic patent ductus arteriosus (PDA), a randomized clinical trial was conducted involving 32 preterm infants weighing 750 to 1500 g at birth who had hyaline membrane disease. " 09/01/1993 - "There was an association of patent ductus arteriosus and phototherapy (p < 0.05) when we analyzed the data with a stepwise regression model that controlled for the effects of gestational age, birth weight, gender, race, diagnosis of hyaline membrane disease, mechanical ventilation, patent ductus arteriosus imaging studies, prophylactic indomethacin, peak total and indirect bilirubin values, and the occurrence of abnormal serum sodium values. "
6.	PhospholipidsIBA 05/01/1983 - "Effect of high-frequency oscillation on gas exchange and pulmonary phospholipids in experimental hyaline membrane disease." 11/01/1970 - "Lung phospholipids of human fetuses and infants with and without hyaline membrane disease." 07/01/1967 - "Lung phospholipids and surface tension correlations in infants with and without hyaline membrane disease and in adults." 12/01/1989 - "The effect of early treatment of patent ductus arteriosus (PDA) on the acute course of hyaline membrane disease was tested in a primate model, after intratracheal administration of 100 mg/kg exogenous bovine surfactant phospholipids at mean ages between 2.3-2.4 h. " 07/01/1988 - "Mixed with appropriate synthetic phospholipids, these proteins may be useful for the treatment of infants with hyaline membrane disease. "
7.	Adrenal Cortex Hormones (Corticosteroids)IBA 02/01/1998 - "Authors compared rates of Hyaline Membrane Disease in infants of patients treated with corticosteroids and of patients who were not. " 06/01/1984 - "[Survey on the use of corticoids for the prevention of hyaline membrane disease in France in 1984]." 01/01/1979 - "In clinical use to date only the corticosteroids have been widely utilized in man but it is clear that these agents are capable of effecting an advancement in the maturation of the surfactant system of the lung and a subsequent reduction in the incidence of severity of hyaline membrane disease. " 11/01/1981 - "Moreover, prenatal maternal administration of corticosteroids has been attended by significantly improved neonatal outcome, including a reduction in the incidences of respiratory distress syndrome (RDS), hyaline membrane disease, and mortality due to intraventricular hemorrhage. " 07/01/1991 - "Because the incidence of both neonatal respiratory distress syndrome and neonatal mortality can be reduced by giving corticosteroids to women expected to deliver preterm and by giving surfactant to babies at high risk of developing hyaline membrane disease, we have considered what effects the adoption of one or both of these preventive policies would have on the costs of neonatal care. "
8.	Congenital diaphragmatic herniaIBA 10/01/2000 - "Infants with hyaline membrane disease and congenital diaphragmatic hernia have also responded positively to the implementation of high-frequency techniques. " 05/01/1994 - "We hypothesized that antenatal glucocorticoid, now the standard treatment to prevent hyaline membrane disease in premature human beings, might correct the parameters of the pulmonary biochemical and morphologic immaturity in severe congenital diaphragmatic hernia. " 01/01/1991 - "Three neonates required ECMO for a congenital diaphragmatic hernia (CDH), two for hyaline membrane disease (HMO), two for meconium aspiration syndrome (MAS), and one for pneumonia. " 01/01/2013 - "Primary etiology included pneumonia and sepsis (30%), hyaline membrane disease (20%), meconium aspiration syndrome (20%) and congenital diaphragmatic hernia (10%). " 05/01/1991 - "Entry diagnoses and aggregate survival were: meconium aspiration syndrome (MAS) 1,356 (93%), persistent pulmonary hypertension of the newborn (PPHN) 480 (83%); congenital diaphragmatic hernia (CDH) 585 (62%); hyaline membrane disease (HMD) 532 (84%); sepsis 416 (77%); and other 185 (77%). "
9.	Morphine (MS Contin)FDA LinkGeneric 07/01/2000 - "The response to morphine (100 microgram (microg)/kg bolus, 10 microg/kg/h infusion) of 14 babies (median birth weight/gestation 1. 37 kg/30 weeks) trigger ventilated for hyaline membrane disease was compared to a group of 26 babies (median birth weight/gestation 1.1 kg/28 weeks) also trigger ventilated for hyaline membrane disease but not treated with morphine. " 06/01/1995 - "Morphine reduces heart rate and respiratory rate without reducing blood pressure, and may help to reduce duration of oxygen therapy in preterm infants with hyaline membrane disease." 07/01/1994 - "Effects of morphine and pancuronium on lung volume and oxygenation in premature infants with hyaline membrane disease." 10/01/1992 - "Ninety-five premature newborns who had hyaline membrane disease and were struggling against the ventilator were randomised to one of three treatment groups: morphine (group M), pancuronium (group P) or morphine with pancuronium (group M+P). " 08/07/1993 - "41 mechanically ventilated babies who had been treated with surfactant (Curosurf) for hyaline membrane disease were randomly assigned morphine in 5% dextrose (100 micrograms/kg per h for 2 h followed by 25 micrograms/kg per h continuous infusion) or 5% dextrose (placebo). "
10.	Betamethasone (Celestone)FDA Link 04/15/1983 - "[Betamethasone in the prevention of pulmonary hyaline membrane disease: the results and applicability of G.C. " 02/01/1975 - "Only one baby of the betamethasone-treated infants died of hyaline membrane disease during the first 7 days of life compared with 11 of the control group. " 11/01/1986 - "Reduced incidence of hyaline membrane disease in extremely premature infants following delay of delivery in mother with preterm labor: use of ritodrine and betamethasone." 03/01/1994 - "Five of the 17 neonates were treated with prenatal betamethasone to attempt to prevent hyaline membrane disease, six received postnatal dexamethasone in an effort to reduce bronchopulmonary dysplasia, three received both, and three were not treated with corticosteroids. " 03/01/2005 - "By univariate analysis for threshold ROP, preeclampsia, prenatal betamethasone exposure, gestational age, birth weight, 1-minute Apgar score, hyaline membrane disease (HMD), surfactant usage, hypotension, septicaemia, intraventricular haemorrhage duration of supplemental oxygen, ventilation and chronic lung disease were associated with ROP requiring surgery (i.e., threshold ROP, P <0.05). "

Therapies and Procedures

1.	Mechanical Ventilators (Ventilator) 07/01/1991 - "As used in this study, HFPPV was the preferred ventilator regimen for infants with hyaline membrane disease." 02/01/1997 - "When lung compliance increased or mean airway pressure decreased, both of which are common events during the recovery phase of hyaline membrane disease, we found that the intrinsic properties of two of the ventilators tested were responsible for a decrease in tidal volume. " 07/01/1995 - "Current recommendations for surfactant replacement therapy (SRT) in the treatment of hyaline membrane disease (HMD) are to administer the drug as soon as possible after starting ventilation in order to prevent ventilator lung damage. " 09/01/1992 - "Eighteen ventilator-dependent preterm infants with hyaline membrane disease were studied for 24 hours before and after an attempt at extubation. " 06/01/1990 - "Nine preterm infants with hyaline membrane disease were studied using a ventilator triggered from abdominal movement. "
2.	Artificial Respiration (Mechanical Ventilation) 06/01/2006 - "Respiratory mechanic dynamics monitoring is beneficial in evaluating the severity of hyaline membrane disease and complications, guiding mechanical ventilation management and weaning." 09/01/1992 - "Both the diagnosis of hyaline membrane disease and the use of mechanical ventilation increased between pre-surfactant and randomized trial periods (hyaline: 47.2% to 55.9%, P less than .05; ventilation: 55.6% to 66.3%, P less than .01). " 09/01/1992 - "Major eligibility criteria for a randomized trial at the Medical University of South Carolina included mechanical ventilation and the diagnosis of hyaline membrane disease. " 09/01/1992 - "To evaluate this concern, the authors reviewed a preexisting database comprising information obtained by trained personnel by chart review to investigate prospectively the frequency of the diagnosis of hyaline membrane disease and the use of mechanical ventilation before and during participation in a clinical trial of surfactant therapy during which such therapy was available exclusively through clinical trials. " 09/01/2015 - "Hyaline membrane disease and mechanical ventilation were also risk factors for respiratory admissions."
3.	Positive-Pressure Respiration (PEEP) 01/01/1989 - "To assess the efficacy of high frequency oscillatory ventilation (HFOV) in the management of infants with hyaline membrane disease (HMD), we compared two HFOV strategies with conventional positive pressure ventilation with positive end expiratory pressure (PPV) for 24 h in premature baboons (140 d gestation). " 03/01/1989 - "To assess the temporal relationship between fluid balance and cardiopulmonary function in hyaline membrane disease (HMD), serial measurements were made of pulmonary gas exchange (Pa/A O2, PaO2, PaCO2), ventilation indices (FIO2, Ppeak, Pmin, frequency), blood pressure (BP), heart rate (HR), and fluid balance ratio (FBR) in 11 premature (140-day gestation) baboons with HMD treated with positive-pressure ventilation and continuous distending airway pressure (PPV/PEEP) for 11 days. " 04/01/1988 - "The results were compared to a group of 16 babies ventilated with classical positive pressure ventilation and presenting with hyaline membrane disease of the same severity. " 07/01/1987 - "We found that elevated RL (greater than +2 SD) at 1 year of age was very significantly related with hyaline membrane disease, involving both high rate of positive pressure ventilation and prolonged intubation, and with the presence of both tachypnea and abnormal chest X rays at the time of discharge. " 01/01/1987 - "Use of total inspiratory pressure-volume curves for determination of appropriate positive end-expiratory pressure in newborns with hyaline membrane disease."
4.	Ligation 10/01/1978 - "Improved lung compliance after ligation of patent ductus arteriosus in hyaline membrane disease."
5.	Neonatal Intensive Care 01/01/2013 - "Babies whose mothers had been allocated to the interventionist group had more intraventricular haemorrhage (RR 1.82, 95% CI 1.06 to 3.14; one study; 262 women), more hyaline membrane disease (RR 2.30, 95% CI 1.39 to 3.81; two studies; 133 women), require more ventilation (RR 1.50, 95% CI 1.11 to 2.02; two studies; 300 women) and were more likely to have a lower gestation at birth in days (average mean difference (MD) -9.91, 95% CI -16.37 to -3.45; four studies; 425 women), more likely to be admitted to neonatal intensive care (RR 1.35, 95% CI 1.16 to 1.58) and have a longer stay in the neonatal intensive care unit (average MD 11.14 days, 95% CI 1.57 to 20.72 days; two studies; 125 women) than those allocated an expectant policy. " 06/01/1996 - "To study the impact of the introduction of artificial surfactant therapy for hyaline membrane disease (HMD) in an Australian neonatal intensive care unit. " 01/01/2000 - "Infants who developed hyaline membrane disease leading to neonatal intensive care admission were also identified. " 10/01/1988 - "[Morbidity and mortality caused by hyaline membrane disease in a neonatal intensive care unit]." 10/25/1980 - "If delivery of a preterm infant is inevitable, the gastric contents can be examined at birth in order to predict whether the baby will develop hyaline membrane disease and should therefore be transferred to a neonatal intensive care unit."